- Revenue Surge Q2 2025 revenue hit $79.2M, up 48% YoY, driven by 46% U.S. and 69% international growth.
- Handpiece Sales Growth Sold 12,750 units (+59% YoY), with 2025 guidance of 53,000 units (64% growth).
- Gross Margin Expansion Improved to 65.4%, a 640 bps YoY increase, from operational efficiencies and higher ASPs.
- CPT Code Milestone Secured Category I CPT code for Aquablation, enhancing clinical adoption and billing standardization.
- EBITDA Guidance 2025 adjusted EBITDA loss narrowed to $35M, with Q4 nearing breakeven, and full-year gross margin at 64.5%.
Key Accomplishments and Future Outlook
Outgoing CEO Reza Zadno highlighted several significant achievements during the quarter. Notably, PROCEPT secured a Category I CPT code for Aquablation therapy, a major milestone that validates the clinical value of the procedure and paves the way for broader adoption. The WATER IV clinical trial, evaluating Aquablation for prostate cancer treatment, is progressing as planned. Further demonstrating the versatility of Aquablation, a successful same-day prostate cancer procedure was performed in an ASC, showcasing the potential for the technology in alternative settings. To optimize the sales execution, PROCEPT is restructuring its commercial team, eliminating the Chief Commercial Officer role and creating new positions for Senior Vice President of Sales and Senior Vice President of Marketing, both reporting directly to incoming CEO Larry Wood.
Financial Guidance and Growth Strategies
The company's focus on high-volume hospitals continues to drive growth, with the recent transition to a Category I billing code for Aquablation therapy expected to further accelerate adoption in 2026. They are also exploring opportunities in lower-volume facilities, which could significantly expand their market reach.